Initiated a Phase 1/2 clinical trial of its lead product

Proteon Initiates Second Phase 1/2 clinical study of PRT-201 in hemodialysis patientsProteon Therapeutics, initiated a Phase 1/2 clinical trial of its lead product, PRT-201, in end-stage renal disease patients operated on for arteriovenous graft creation. The AVG study represents Proteon the second clinical study in hemodialysis patients, the . Before the opening of a phase 1/2 study of PRT-201 in patients with end stage renal surgery for arteriovenous fistula creation earlier this year Proteon also the appointment of board member Gregory D. Phelps as Chairman of the Board of Directors. President and CEO of Proteon. We are now active patient enrollment in two separate double-blind, Placebo-controlled phase 1/2 clinical studies in humans using PRT-201 in AVF and AVG surgical settings. Greg was appointed Chairman of the Board, our team with even better access to his wealth of strategic and operational experience at an important stage of Proteon development. .

Greg Phelps has more than 30 years experience in the medical products and biotechnology Chief Executive Officer Chief Executive Officer, Board Director and senior management positions in several companies holding. He is co-founder and partner of Red Sky Partners LLC, focusing team of experienced healthcare executives to new ventures in clinical development and strategic consulting in the life sciences field. Greg has been the Chairman and CEO of renamed Biologics Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation, Vice President held the Baxter Travenol Laboratories and as CEO of Ardais Corporation, Viagene, and ZymoGenetics, He’s on the boards of directors of ten public and private healthcare companies and two nonprofit organizations served. Greg holds example in electrical engineering from Bradley University and an MBA from Harvard Business School.

You spent six months in hospital and had to learn all the essential abilities like walking, talking, dressing and eating in case of contact. The blind for the blind, Nichola was partial at Durham research.

Hemianopsia affecting more than 4,000 people in the UK each year. Sufferers will lose half their field of vision by a stroke or other cerebral trauma. It depend heavily on other them fight with balance, walking, finding things Dr and they usually normally in a position.

Other Posts From Category "manual therapy":

Related Posts